Status: Recruiting
Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma
This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.
Participants needed: 29
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Renmin Hospital of Wuhan UniversityUpdated: Oct 3, 2022Locations: 1
Eligibility criteria
All individuals recruited signed a written informed consent; [+9]
Other malignancy disease history within five years, with the exception of basal... [+17]